Novartis: Multiple Myeloma trials
The registry lists 42 Multiple Myeloma studies with Novartis as lead sponsor. 0 are open to participants now and 14 have results posted.
Phase 1 21Phase 2 15Phase 3 2Phase 4 5No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM)TerminatedNCT03340883Phase 1/2Results posted
- A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)TerminatedNCT02720510Phase 2Results posted
- Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT02290431Phase 2Results posted
- Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare CancersCompletedNCT02034110Phase 2Results posted
- Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood TransplantCompletedNCT01930162Phase 2Results posted
- Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating FactorCompletedNCT01459653Results posted
- A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple MyelomaCompletedNCT01421186Phase 1/2Results posted
- Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple MyelomaCompletedNCT01083602Phase 2Results posted
- Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple MyelomaCompletedNCT01023308Phase 3Results posted
- Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma ParticipantsCompletedNCT00622505Phase 4Results posted
- A Study of Oral LBH589 in Adult Patients With Advanced Hematological MalignanciesCompletedNCT00621244Phase 1/2Results posted
- Efficacy and Safety of LBH589B in Adult Patients With Multiple MyelomaTerminatedNCT00445068Phase 2Results posted
- Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage ITerminatedNCT00171925Phase 3Results posted
- A Multiple Myeloma Trial in Patients With Bone MetastasesCompletedNCT00104104Phase 4Results posted
- PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple MyelomaTerminatedNCT05172596Phase 2
- VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)TerminatedNCT04702425Phase 1
- BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple MyelomaTerminatedNCT04318327Phase 1
- A Study of WVT078 in Patients With Multiple Myeloma (MM)TerminatedNCT04123418Phase 1
- Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple MyelomaCompletedNCT03111992Phase 1
- Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple MyelomaCompletedNCT02992483Phase 1
- Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple MyelomaWithdrawnNCT02756663Phase 2
- An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple MyelomaNo longer availableNCT02568943
- A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)TerminatedNCT02235740Phase 1
- Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple MyelomaNo longer availableNCT02204553
- Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma PatientsTerminatedNCT02177682Phase 1
- Dose Escalation Study of LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic MalignanciesCompletedNCT02160951Phase 1
- Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple MyelomaCompletedNCT02144038Phase 1
- A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple MyelomaCompletedNCT01456689Phase 1
- Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple MyelomaCompletedNCT01428492Phase 1
- Study in Patients With Untreated Multiple Myeloma and Renal InsufficiencyCompletedNCT01337752Phase 2
- Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal TranslocationCompletedNCT01058434Phase 2
- A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma PatientsCompletedNCT00741377Phase 1
- A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.CompletedNCT00708292Phase 1/2
- Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.CompletedNCT00532675Phase 1
- Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple MyelomaCompletedNCT00532389Phase 1
- Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone MetastasesCompletedNCT00434447Phase 4
- Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior YearCompletedNCT00424983Phase 1
- TKI258 in Subjects With Refractory or Relapsed Multiple MyelomaTerminatedNCT00243763Phase 1
- Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.WithdrawnNCT00242528Phase 4
- Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple MyelomaCompletedNCT00231166Phase 1
- Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare DiseasesCompletedNCT00154388Phase 2
- Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone LesionsCompletedNCT00029224Phase 4